Crossmark

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12885-019-5481-z

Published Online: 2019-03-28

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zheng, Bobo

Wang, Xin

Wei, Mingtian

Wang, Quan

Li, Jiang

Bi, Liang

Deng, Xiangbing

Wang, Ziqiang http://orcid.org/0000-0002-0410-2640
License Information

Text and Data Mining valid from 2019-03-28
More Information

Article History

Received: 19 May 2018

Accepted: 15 March 2019

First Online: 28 March 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.